Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kymera Therapeutics, Inc. - Common Stock (NQ:KYMR)

45.18 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kymera Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Kymera Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 23
Company also presenting at upcoming investor conferences 
From Kymera Therapeutics, Inc.
Via GlobeNewswire
X-Chem and Kymera Expand Existing Partnership
From X-Chem
Via Business Wire
What 4 Analyst Ratings Have To Say About Kymera Therapeutics
Via Benzinga
Looking Into Kymera Therapeutics's Return On Capital Employed
Via Benzinga
Where Kymera Therapeutics Stands With Analysts
Analysts have provided the following ratings for Kymera Therapeutics (NASDAQ:KYMR) within the last quarter: 
Via Benzinga
Kymera Therapeutics Shares Key 2023 Goals to Support its Evolution into a Fully Integrated Degrader Medicines Company
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Appoints Ellen Chiniara, J.D., as Chief Legal Officer and Corporate Secretary
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023
From Kymera Therapeutics, Inc.
Via GlobeNewswire
5 Analysts Have This to Say About Kymera Therapeutics
Analysts have provided the following ratings for Kymera Therapeutics (NASDAQ:KYMR) within the last quarter: 
Via Benzinga
7 Perfect Presents to Gift Your 2023 Stock Portfolio
As we leave 2022 behind, these hot stocks to buy have significant potential and serious catalysts as we move into New Year 2023. 
Via InvestorPlace
Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 50 Stocks Moving In Wednesday's Mid-Day Session
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share. 
Via Benzinga
These Biotech Stocks Are the Nasdaq's Big Wednesday Winners
Business wins are shining the spotlight on these two companies. 
Via The Motley Fool
Dear DS Stock Fans, Mark Your Calendars for Dec. 23
Drive Shack (DS) stock is falling hard on Wednesday after the company warned investors of it delisting shares this month. 
Via InvestorPlace
Why Is SOFI Stock Up 7% Today?
SoFi Technologies (SOFI) stock is climbing higher on Wednesday after the company's CEO bought over 1 million more shares. 
Via InvestorPlace
Dear CRKN Stock Fans, Mark Your Calendars for Dec. 22
Crown Electrokinetics (CRKN) stock is on the move Wednesday as investors prepare for the company's upcoming shareholder meeting. 
Via InvestorPlace
Why Is Kymera Therapeutics (KYMR) Stock Up 20% Today?
KYMR stock traders are bidding up the share price today as Kymera Therapeutics teams up to take a skin condition treatment to the next phase. 
Via InvestorPlace
REV Group, Avidity Biosciences And Some Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Kymera Therapeutics Stock Jumps After Positive Data From Atopic Dermatitis Trial
Via Benzinga
US Stocks Higher Ahead Of Fed Decision
U.S. stocks traded higher this morning, with the Dow Jones gaining over 80 points on Wednesday 
Via Benzinga
Why Small Biotech Kymera Just Snagged Sanofi's Interest And Surged 28%
The company is working on protein degradation in cancer and inflammatory diseases. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Kymera Announces Positive Results from Phase 1 Clinical Trial Evaluating KT-474 in Patients with HS and AD and Sanofi’s Decision to Advance KT-474 into Phase 2 Clinical Trials
From Kymera Therapeutics, Inc.
Via GlobeNewswire
JetBlue Airways, Pacira BioSciences And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded slightly higher, with the Nasdaq Composite gaining around 70 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Preclinical Data from Kymera Therapeutics’ Collaborations Demonstrate Therapeutic Potential of STAT3 Degraders in CTCL and IRAKIMiD Combination with BCL-2 Inhibitor in MYD88-Mutant DLBCL at the American Society of Hematology Annual Meeting
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at the American Society of Hematology Annual Meeting
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2022
Via Benzinga
JPMorgan To Rally Around 17%? Here Are 10 Other Price Target Changes For Tuesday
Via Benzinga
Kymera Therapeutics Provides Webcast Information for December 14 Investor Event
Company to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline 
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2022
Upgrades 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.